Ductal carcinoma in situ of the breast: MR imaging findings with histopathologic correlation

Radiographics

Volumn 30, Issue 6, 2010, Pages 1673-1687

  Mossa Basha, Mahmud ^a   Fundaro, Gina M ^a   Shah, Biren A ^a   Ali, Sharif ^a   Pantelic, Milan V ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GADOBENIC ACID; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; BIOPSY; BREAST TUMOR; CASE REPORT; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; MAMMOGRAPHY; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PAGET NIPPLE DISEASE; PATHOLOGY; THREE DIMENSIONAL IMAGING;

ADULT; AGED; BIOPSY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS;

EID: 78149378871     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.306105510     Document Type: Article

References (42)

1. Brown PW, Silverman J, Owens E, Tabor DC, Terz JJ, Lawrence W Jr. Intraductal "noninfiltrating" carcinoma of the breast. Arch Surg 1976;111(10): 1063-1067.
2. Dershaw DD, Abramson A, Kinne DW. Ductal carcinoma in situ: mammographic findings and clinical implications. Radiology 1989;170(2):411-415.
3. Lagios MD, Westdahl PR, Rose MR. The concept and implications of multicentricity in breast carcinoma. Pathol Annu 1981;16(pt 2):83-102.
4. Faverly DR, Burgers L, Bult P, Holland R. Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications. Semin Diagn Pathol 1994;11(3):193-198.
5. Holland R, Hendriks JH, Vebeek AL, Mravunac M, Schuurmans Stekhoven JH. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet 1990;335 (8688):519-522.
6. Allegra CJ, Aberle DR, Ganschow P, et al. Diagnosis and management of ductal carcinoma in situ (DCIS). NIH Consens State Sci Statements 2009; 26(2):1-27.
7. Orel SG, Mendonca MH, Reynolds C, Schnall MD, Solin LJ, Sullivan DC. MR imaging of ductal carcinoma in situ. Radiology 1997;202(2):413-420.
8. Recht A, Rutgers EJ, Fentiman IS, Kurtz JM, Mansel RE, Sloane JP. The Fourth EORTC DCIS Consensus Meeting (Château Marquette, Heemskerk, The Netherlands, 23-24 January 1998): conference report. Eur J Cancer 1998;34(11):1664-1669.
9. Farshid G, Downey P, Gill PG. Atypical presentations of screen-detected DCIS: implications for preoperative assessment and surgical intervention. Breast 2007;16(2):161-171.
10. Lee SG, Orel SG, Woo IJ, et al. MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. Radiology 2003;226(3):773-778.
11. Mokbel K. Current management of ductal carcinoma in situ of the breast. Int J Clin Oncol 2003;8 (1):18-22.
12. Stomper PC, Connolly JL, Meyer JE, Harris JR. Clinically occult ductal carcinoma in situ detected with mammography: analysis of 100 cases with radiologic- pathologic correlation. Radiology 1989;172 (1):235-241.
13. Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressman P; Consensus Conference Committee. The Consensus Conference on the Treatment of In Situ Ductal Carcinoma of the Breast, 22-25 April 1999. Breast 2000;9(4):177-186.
14. Fisher ER, Sass R, Fisher B, Wickerham L, Paik SM. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DCIS). Cancer 1986;57(2):197-208.
15. Fisher B, Costantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993;328(22):1581-1586.
16. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16(2):441-452.
17. Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853-EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000;355(9203):528-533.
18. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353(9169): 1993-2000.
19. Holland R, Connolly JL, Gelman R, et al. The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol 1990;8(1):113-118.
20. Sinn HP, Anton HW, Magener A, von Fournier D, Bastert G, Otto HF. Extensive and predominant in situ component in breast carcinoma: their influence on treatment results after breast-conserving therapy. Eur J Cancer 1998;34(5):646-653.
21. Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 2004;233(3): 830-849.
22. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002;94(20):1546-1554.
23. Menell JH, Morris EA, Dershaw DD, Abramson AF, Brogi E, Liberman L. Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging. Breast J 2005;11(6):382-390.
24. Rosen EL, Smith-Foley SA, DeMartini WB, Eby PR, Peacock S, Lehman CD. BI-RADS MRI enhancement characteristics of ductal carcinoma in situ. Breast J 2007;13(6):545-550.
25. Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet 2010;375 (9714):563-571.
26. Morris EA. ACR practice guideline for the performance of contrast-enhanced magnetic resonance imaging (MRI) of the breast. Reston, Va: American College of Radiology, 2008.
27. Liberman L, Morris EA, Dershaw DD, Abramson AF, Tan LK. MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer. AJR Am J Roentgenol 2003;180(4):901-910.
28. Liberman L, Morris EA, Kim CM, et al. MR imaging findings in the contralateral breast of women with recently diagnosed breast cancer. AJR Am J Roentgenol 2003;180(2):333-341.
29. Renz DM, Böttcher J, Baltzer PA, et al. The contralateral synchronous breast carcinoma: a comparison of histology, localization, and magnetic resonance imaging characteristics with the primary index cancer. Breast Cancer Res Treat 2010;120(2):449-459.
30. Gilles R, Zafrani B, Guinebretière JM, et al. Ductal carcinoma in situ: MR imaging-histopathologic correlation. Radiology 1995;196(2):415-419.
31. Jansen SA, Newstead GM, Abe H, Shimauchi A, Schmidt RA, Karczmar GS. Pure ductal carcinoma in situ: kinetic and morphologic MR characteristics compared with mammographic appearance and nuclear grade. Radiology 2007;245(3):684-691.
32. Heywang-Köbrunner SH. Contrast-enhanced magnetic resonance imaging of the breast. Invest Radiol 1994;29(1):94-104.
33. Harms SE, Flamig DP, Hesley KL, et al. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 1993;187(2):493-501.
34. Uematsu T, Yuen S, Kasami M, Uchida Y. Comparison of magnetic resonance imaging, multidetector row computed tomography, ultrasonography, and mammography for tumor extension of breast cancer. Breast Cancer Res Treat 2008;112(3):461-474.
35. Viehweg P, Lampe D, Buchmann J, Heywang- Köbrunner SH. In situ and minimally invasive breast cancer: morphologic and kinetic features on contrastenhanced MR imaging. MAGMA 2000;11(3): 129-137.
36. Harms SE. The use of breast magnetic resonance imaging in ductal carcinoma in situ. Breast J 2005; 11(6):379-381.
37. Ozzello L. Ultrastructure of intra-epithelial carcinomas of the breast. Cancer 1971;28(6):1508-1515.
38. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ: frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989;63(4):618-624.
39. Bellamy CO, McDonald C, Salter DM, Chetty U, Anderson TJ. Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum Pathol 1993;24(1):16-23.
40. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma-insitu. Lancet 1995;345(8958):1154-1157.
41. National Cancer Institute. SEER Cancer Statistics Review, 1975-2007. http://seer.cancer.gov/csr/1975_2007/. Published 2010. Accessed June 11, 2010.
42. Harris EE, Schultz DJ, Jones HA, Solin LJ. Factors associated with residual disease on re-excision in patients with ductal carcinoma in situ of the breast. Cancer J 2003;9(1):42-48.